Telmisartan is an antihypertensive drug that belongs to the class of angiotensin II receptor blockers. It has been shown to offer several benefits beyond reducing high blood pressure, including improved insulin sensitivity, increased utilization of fat as energy, and improved mitochondrial function. Among the drugs in this class, telmisartan stands out as superior for potential longevity enhancement.
As we age, mitochondrial dysfunction becomes a significant factor in the development of obesity, insulin resistance, and type 2 diabetes. Telmisartan helps correct these underlying mechanisms of aging and death by activating the regulator of cellular energy called PPAR-gamma coactivator 1 alpha (PGC-1a), which stimulates the burning of excess calories, and has been shown to be a crucial factor in weight management. Studies have also shown that telmisartan stimulates PPAR-gamma, a key inducer of beneficial metabolic effects, at least 10 times more effectively than other drugs in its class.
In addition, telmisartan has been shown in preclinical models to reduce weight gain, increase total energy expenditure, and improve the expression of key mitochondrial enzymes in skeletal muscle better than other popular drugs in this class. It also functions to protect against arterial occlusion, including increasing beneficial endothelial nitric oxide, and may promote biochemical, biological, and metabolic effects that some researchers have suggested could boost athletic performance.
Telmisartan increases expression of genes such as BuBR1 and decreases the expression of p70 S6 Kinase, leading to potential benefits such as improved insulin sensitivity, reduced cognitive decline, delayed aging-related diseases, slowed cardiac aging, increased resistance to bone, immune and motor dysfunction, tissue rejuvenation, and an extended lifespan. Lower dose combinations of telmisartan or its analogues with other drugs may also be used to prolong lifespan.